Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
XXXX: leaving its' bottom of .15
LWLG bonkers today on recent news (no promo), looks overextended at close to $3.00, so maybe a short for the very brave -- or a bounce play if it takes a quick drop.
I sense a ban coming....
VASO said in yesterday's PR that next quarter will be even better than this one. Could be an easy 2-3 bagger from here!
"Due to the nature of our commission structure under the agreement with GEHC, we earn progressively higher commission rates as calendar year targets are met. As we achieve these targets the higher commission rates are retroactive to the beginning of the calendar year, and therefore we anticipate earning and recognizing greater revenue in the fourth quarter of the calendar year."
VASO is holding most of its gains nicely at .26 x .275, but their statement about next quarter being better than this one seems not to have been noticed by the big money yet....
It would be correct to say that most (but not all) of those trades were at the offer. However, there was a seller for every one of those shares.
VASO nice move on record volume, had had a wall at .29 but that is now gone
They certainly helped their stock today by writing a nice, professional PR, with an optimistic look toward next quarter. Can't get much clearer than this:
we anticipate earning and recognizing greater revenue in the fourth quarter of the calendar year
There are some lingering non-believers offering stock at .28-.29, but I don't see why the stock shouldn't continue creeping up into at least the .40-.50 range once word spreads.
Yep. "VasoHealthcare, our sales representative subsidiary which represents GE Healthcare ("GEHC") for the sale of select diagnostic imaging products on an exclusive basis to specific market segments in the 48 contiguous states of the United States and Washington, DC"
"Actual company"? Another yep. VASO has been marketing EECP devices since at least the mid-'90s.
Looks like other people are doing the same thing. You don't often see 47 consecutive trades at the offer (except with manipulated scam stocks, which VASO is clearly not).
EDIT: I jinxed it :). Someone hit the .25 bid.
Now highest daily volume for VASO since last April when it was over .70.
Yep. NITE's .23 wall is finally gone. The last 35-40 prints have been at the offer.
It looks like they should be ramping up nicely for the rest of their fiscal year.
"As we achieve these targets the higher commission rates are retroactive to the beginning of the calendar year, and therefore we anticipate earning and recognizing greater revenue in the fourth quarter of the calendar year."
PRESS RELEASE
Jan. 17, 2012, 8:30 a.m. EST
Vasomedical Recorded Record Net Income of $2.47 Million for the Second Quarter of Fiscal 2012
Company Reports 181% Year over Year Increase in Revenue for the Six Months Ended November 30, 2011
WESTBURY, N.Y., Jan 17, 2012 (BUSINESS WIRE) -- Vasomedical, Inc. ("Vasomedical") , a leader in the manufacture and sale of devices for the non-invasive treatment and management of cardiovascular diseases and a leader in the sale of diagnostic imaging products, today reported financial results for the quarter ended November 30, 2011. These results include the operations of its wholly-owned subsidiaries, Vaso Diagnostics, Inc., d/b/a VasoHealthcare, our sales representative subsidiary which represents GE Healthcare ("GEHC") for the sale of select diagnostic imaging products on an exclusive basis to specific market segments in the 48 contiguous states of the United States and Washington, DC, and the recently acquired Chinese companies.
The Company recorded revenue of $9.95 million and $14.28 million for the three and six month periods ended November 30, 2011, respectively, compared to revenue of $3.80 million and $5.08 million for same periods a year ago, an increase of 161.9% and 181.3% for the three and six month periods, respectively . The increase is primarily due to an increase in commission revenue at VasoHealthcare, as the agreement with GE Healthcare, which began mid-year 2010, was in full operation in 2011 and the Company earned higher commission rates in 2011 as a result of achieving certain performance targets. Due to the nature of our commission structure under the agreement with GEHC, we earn progressively higher commission rates as calendar year targets are met. As we achieve these targets the higher commission rates are retroactive to the beginning of the calendar year, and therefore we anticipate earning and recognizing greater revenue in the fourth quarter of the calendar year. We continue to record substantial amounts of deferred revenues, which will be recognized once the underlying equipment or service is accepted or performed. As of November 30, 2011, total deferred revenues were approximately $14.7 million, an increase of $2.6 million and $2.8 million from August 31, 2011 and May 31, 2011, respectively.
Net income for the quarter and six months ended November 30, 2011 was $2.47 million and $816,000, respectively, compared to a net loss of $1.13 million and $3.70 million for the same periods in the prior year. The significant change from net loss to net income is attributable to the increase in commission revenue, as discussed above, offset by the related increase in commission expense. Income attributable to common stockholders was $1.33 million or $0.01 per common share for the three months ended November 30, 2011, compared to a net loss of $1.26 million or ($0.01) per common share for the three months ended November 30, 2010. The significant change from net loss to net income is attributable to the increase in commission revenue, as discussed above, offset by the related increase in commission expense. For the six months ended November 30, 2011 net loss attributable to common stockholders was $406,000 or $0.0 per share compared to a net loss applicable to common stockholders of $3.85 million or ($0.03) per share for the same period in the prior year. The net loss applicable to common stockholders is after reduction for preferred stock dividends of $1.14 million and $125,000 for the three months ended November 30, 2011 and 2010, respectively, and $1.22 million and $152,000 for the six months ended November 30, 2011 and 2010, respectively. These preferred stock dividends are noncash items resulting principally from the value of the imbedded beneficial conversion feature in the preferred stock.
"We are very excited by achieving significant record profitability during this reporting period and are gratified with the significant revenue growth from our VasoHealthcare operations," commented Dr. Jun Ma, Chief Executive Officer and President of Vasomedical. "This result, combined with our recent acquisition of Life Enhancement Technology Ltd. and BIOX Instruments Co. Ltd., gives us a stronger position in the marketplace, enhanced product offerings and positions us to achieve our global vision while enhancing our growth potential," said Dr. Ma.
About Vasomedical
Vasomedical, Inc. is primarily engaged in designing, manufacturing, marketing and supporting EECP(R) external counterpulsation systems based on the Company's proprietary technology. EECP(R) therapy is a non-invasive, outpatient therapy for the treatment of cardiovascular diseases and is currently indicated for use in cases of angina, cardiogenic shock, acute myocardial infarction and congestive heart failure. The Company provides hospitals, clinics and private practices with EECP(R) equipment, treatment guidance and a staff training and maintenance program designed to provide optimal patient outcomes. The Company also provides other noninvasive medical equipment including Holter monitors and ambulatory blood pressure monitors.
Vaso Diagnostics d/b/a VasoHealthcare, a wholly owned subsidiary of Vasomedical, Inc., is a professional sales representation organization offering vendors of medical devices an alternative third party sales channel. Through an agreement with GE Healthcare, it is currently engaged as an exclusive sales representative for certain GE Healthcare products. Additional information is available on the Company's website at www.vasomedical.com .
Summarized Financial Information
FOR THE THREE MONTHS ENDED FOR THE SIX MONTHS ENDED
--------------------------------------- ---------------------------------------
STATEMENT OF OPERATIONS November 30, 2011 November 30, 2010 November 30, 2011 November 30, 2010
----------------------------------------------------- ------------------- ------------------- ------------------- -------------------
Revenue from operations $ 9,953,000 $ 3,801,000 $ 14,282,000 $ 5,077,000
Gross profit $ 7,392,000 $ 2,362,000 $ 10,219,000 $ 3,000,000
Operating income (loss) $ 2,463,000 $ (1,153,000) $ 779,000 $ (3,730,000)
Other income, net $ 30,000 $ 23,000 $ 63,000 $ 36,000
Income (loss) before income taxes $ 2,493,000 $ (1,130,000) $ 842,000 $ (3,694,000)
Provision for income taxes $ (24,000) $ (1,000) $ (26,000) $ (7,000)
Net income (loss) $ 2,469,000 $ (1,131,000) $ 816,000 $ (3,701,000)
Preferred stock dividends $ (1,136,000) $ (125,000) $ (1,222,000) $ (152,000)
Net income (loss) attributable to common stockholders $ 1,333,000 $ (1,256,000) $ (406,000) $ (3,853,000)
===== ========== ===== ========== = ===== ========== = ===== ========== =
Basic and diluted income (loss) per share $ 0.01 $ (0.01) $ (0.00) $ (0.03)
===== ========== ===== ========== = ===== ========== = ===== ========== =
BALANCE SHEET November 30, 2011 May 31, 2011
------------------------- -------------------- ------------------
Total Current Assets $ 22,989,000 $ 17,372,000
Total Assets $ 27,078,000 $ 18,555,000
Total Current Liabilities $ 17,680,000 $ 14,536,000
Total Stockholders Equity $ 6,945,000 $ 2,908,000
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as "anticipates", "believes", "could", "estimates", "expects", "may", "plans", "potential" and "intends" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.
SOURCE: Vasomedical, Inc.
Vasomedical, Inc.
Investor Relations:
Dr. Jun Ma, 516-997-4600
President and CEO
or
Michael J. Beecher, 516-997-4600
CFO
ir@vasomedical.com
VASO - more to come next quarter!
"As we achieve these targets the higher commission rates are retroactive to the beginning of the calendar year, and therefore we anticipate earning and recognizing greater revenue in the fourth quarter of the calendar year."
That is huge. I just read this again:
"As we achieve these targets the higher commission rates are retroactive to the beginning of the calendar year, and therefore we anticipate earning and recognizing greater revenue in the fourth quarter of the calendar year."
I am in. It is close to the bottom of the chart as well, so .40-.50 seems completely reasonable.
Without something in that picture for scale, I can't tell whether Bob is actually short.
XRMB closed with a flurry of 10,000 blocks but ALPS still has some size on the offer
Shhhh. Don't tell my kids or employer. I have enough trouble trying to explain this tinfoil hat.
Nothing to do with shorting. That is my bid.
Like cheese? Hmmm, it has holes in it? It smells bad? It has mold running through it? Nope, I guess you must mean a different kind of cheese...
I haven't heard from Curber in a couple of months. I had an email exchange with Rick about a month ago and may say hello to him again soon, just to get a sense of his mood.
No. Read and try to understand the rest of that guy's post. Daily "short volume" is not "short interest."
His "conspiracy" comment pertained to that other company, not to PAOS.
EDIT, TO THE MODS: I don't know which of you overzealous mods deleted my link to that post, but it was the definitive explanation of the FINRA "short volume" numbers and not "spam." Sheesh. Getting it reverted.
I guess she didn't get the memo.
Will you guys PLEASE stop jumping my bids :)
I wonder if he's any better at returning phone calls than his father was.
Seller's remorse.
Jovovich, I presume:
Wow, That Snapped Back In A Milla Second!
Right, but we are thinking that for vastly different reasons.
UBSS was the .019 bidder yesterday for 90,000 shares. A block of 80-something thousand hit the bid but must have been matched up in-house by another MM, because the bid didn't budge.
"We know he is considered the "President" or owner of the AIMH shell according to the Nevada SOS, but we still have no idea what the reverse-merging company is, what they do, and who their directors are. For all we know he could be a temporary middle man until the reverse-merging company is ready to seal the deal. I really don't know, just throwing things out there."
Well said, Alex. Marchi may be the guy who is brokering the deal. I've been trying to figure out why a career penny-stock guy who just left one company would be getting involved with another (particularly when I think Morey could do better than turn the shell over to a questionable penny-stock guy), and that speculation is as good as any.
Shooting him would get him off of the air [sic]
I think he meant to say
get them while your their!!
Gave you #58 just for that photo! -Satguy
Looks like the joker I was referring to yesterday showed up today :)
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=70710506
There are some really dumb people out there. Like the guy who wanted to buy stock at .019 when the ask was .023, but now that there's a 50,000 seller at .0228 he gets scared and pulls his bid. My feeling is, either you want to buy the stock or you don't. Why be frightened of someone selling $1,200 worth?
EDIT: OK, maybe that's him now at .02 bid. That makes more sense, if he was trying to entice the .0228 guy to come down and hit him, but ooops! -- someone else just got there first.
Sigh.
didn't get all I wanted so I am waiting with baited breath to add more at .02 or chase
GLYE needs a catalyst to get it to start trading. One PR could do it.
"Morey wouldn't have chosen them if it wasn't going to be very beneficial for the comapny and the shareholders."
Agreed. He is a smart guy, obviously knew he had a valuable asset, and was in no hurry to make a mediocre deal. I'm looking forward to seeing the press release.
Yep. It is real. A reverse merger is happening. The change in officers confirms it.
But it has nothing to do with Conexant.
Alex, please, you really need to stop posting ridiculous things. As Joby and Homer said, let's keep it real. Speculative nonsense is more likely to drive away potential buyers of AIMH than attract them.
It's not "the Conexant building." It is just an office building, and a company that was just acquired by a private equity firm last year is not going to go public again through a shell. Here is a partial list of tenants of 4000 MacArthur Blvd.:
Avalar Real Estate
Bozzwell Communications Inc
California Self Storage Association
Castle and Cooke Mortgage LLC of Orange County
Conexant Systems Inc
Dave's Detailing-Beach Cities
Emcor Energy & Technologies
HCS Technologies, LLC
Hot Rail Inc
Maker Communications Inc
Mindspeed Technologies Inc
Oak Bridge Advisors Inc
Prediction Probe
Premier Office Center Llc
Simpson Gumpertz & Heger